Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
2 Aprili 2026, 11:46:47
Abatacept na ujauzito
Imeboreshwa:
Abataceptni dawa aina ya fusion protein, inayofanya kazi ya kuzuia seli za ulinzi zenye jina la T-lymphocyte kuamshwa ili kufanya kazi, kwa kufanya hivi huzuia uzalishaji wa seli hizi za ulinzi na kuzuia uzalishaji wa kemikali zacytokine na tumor necrosis factor-α, interferon-γ, na interleukin-2 zinazoamsha maumivu, uvimbe na homa kwa wagonjwa wenye baridi yabisi. Dawa hii hutumika yenyewe au na zingine kutibu dalili za wastani au kali kwa wagonjwa walioshindikana kwa dawa zingine.
Ushauri dhidi ya matumizi kwa mama mjamzito
Hakuna (zipo chache) taarifa za binadamu- taarifa za wanyama zinaonyesha kuwepo hatari kidogo
Ushauri wa matumizi kwa mama anayenyonyesha
Hakuna taarifa za binadamu- Inaweza kuwa sumu
ULY Clinic inakushauri uwasiliane na daktari wako siku zote kabla ya kufanya maamuzi yanayohusisha afya yako
Wasiliana na daktari wa ULY Clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kutumia namba za simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeandikwa:
2 Aprili 2026, 11:41:58
Rejea za dawa
Moghadam-Kia S, Oddis CV, Aggarwal R. Safety of Biologic Therapies in Pregnant Patients with Rheumatic Diseases. Best Pract Res Clin Rheumatol. 2016;30(5):794-808.
Förger F, Zbinden A, Villiger PM. Pregnancy and Rheumatic Diseases: Effects on Disease Activity and Pregnancy Outcome. Swiss Med Wkly. 2012;142:w13642.
Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52(2):514-21.
European Medicines Agency (EMA). Orencia (abatacept): Summary of product characteristics. 2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/orencia
Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to abatacept. Arthritis Rheum. 2011;63(4):837-42.